The TIGIT inhibitor tiragolumab is currently being used primarily in combination with anti-PD-L1 drugs in clinical trials in HNSCC, with two phase II studies (NCT03708224 and NCT04665843) underway. The gene discussed is TIGIT; the disease is head and neck squamous cell carcinoma.